# Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

> **NCT01462578** · PHASE2 · COMPLETED · sponsor: **Technische Universität Dresden** · enrollment: 93 (actual)

## Conditions studied

- Acute Myelocytic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01462578
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2018-08
- **Final completion:** 2021-02
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462578, "Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01462578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*